Contraception, pregnancy and weight-loss medication

If you could become pregnant, three things follow from starting one of these treatments, and they are specific rather than general cautions.

You need effective contraception throughout. If you are taking tirzepatide and your contraception is an oral one, the licence asks for an additional step at particular moments. And if you want to conceive, there is a defined gap between stopping the medicine and trying, which is longer for semaglutide than for tirzepatide.

None of this makes treatment unavailable. It changes the plan around it, which is a conversation worth having at assessment rather than six weeks in.

These medicines slow the rate at which the stomach empties. That is part of how they produce fullness, and it also changes the absorption of anything swallowed — including a contraceptive pill.

For tirzepatide this has been measured. Taken alongside a combined oral contraceptive, peak concentration of the progestogen component fell by around two-thirds and total exposure by around a fifth. In people of normal BMI the licence judges that reduction not to be clinically relevant and asks for no change.

The caveat is the important part. Information is limited in people who are overweight or obese, which is the population actually being treated, and reduced effectiveness there cannot be excluded. So the licence advises switching to a non-oral method of contraception, or adding a barrier method, rather than assuming the pill is unaffected.

Semaglutide and liraglutide do not carry the same specific contraceptive advice. Effective contraception is still expected while taking them — that part applies to the whole class.

This is the detail people miss, and missing it is how the precaution fails.

The tirzepatide licence asks for the additional method for four weeks when you start treatment, and for four weeks after each dose escalation. Not only at the beginning.

The logic follows from the mechanism: each increase in dose produces a fresh change in gastric emptying, so each one re-opens the same question about absorption. Someone titrating from 2.5 mg through 5, 7.5 and 10 mg passes through that window several times over several months, with ordinary weeks in between.

The practical consequence is that a dose increase is a date worth noting, and the weekly record described in our tracking guide happens to capture exactly the information this requires.

These medicines are not used in pregnancy. There is not enough safety data to know whether they can harm a developing baby, and the regulatory position is precautionary rather than reassuring.

The MHRA advises stopping before trying to conceive, and the interval differs by molecule — it follows how long each takes to clear.

Stop the medicine and contact a clinician — your prescriber, your GP or your midwife. Do not wait for a scheduled review, and do not take the next weekly dose while you work out what to do.

An unplanned pregnancy on one of these treatments is not a catastrophe and it is not a reason to avoid medical contact. The absence of safety data is the reason for caution; it is not evidence of harm. What it means is that the pregnancy should be known about and managed by people who have the full picture.

Two further things are worth knowing. Weight loss itself can restore fertility in people whose ovulation had been affected by weight, so pregnancy can become more likely during treatment than it was before it — a genuinely common surprise. And the contraception caveat above means that for some people, the method they were relying on was less reliable than they assumed.

These medicines are not recommended while breastfeeding. It is not known whether they pass into human milk, and as with pregnancy the position reflects absent data rather than demonstrated harm.

If you are considering restarting treatment after a birth, that timing is a clinical conversation rather than a fixed rule, and it depends on feeding plans as much as on the medicine.

Raise it at assessment rather than later, even if pregnancy is not in your plans. The assessment asks about pregnancy, but it is worth volunteering what contraception you use, because the answer changes what the prescriber recommends alongside the treatment.

Raise it again at each dose increase if you are on tirzepatide and using an oral contraceptive, because that is when the four-week window reopens.

And raise it as soon as plans change. Deciding to try for a baby is a reason to review the treatment, and the gap required beforehand means the conversation is more useful months ahead than weeks.